Changing Lives of
with Gene Therapy
Atamyo’s mission is to bring a new generation of best-in-class gene therapies to patients suffering from neuromuscular diseasesRead more
My goal is to be like everyone else and to have them forget my disabilityRead Patient Stories
The name of the company is derived from two words: Atao which means “Always” or “Forever” in a Celtic language and myo which is the Greek root for everything muscle-related. This name conveys the spirit of the company in its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.
At Atamyo, we use our expertise in gene therapy and muscular dystrophies to find new approaches for gene replacement.
Our goal is to design the best delivery system for a particular disorder, in order to decrease side effects and improve the restoring of a normal physiological function.
Diseases & Patient Communities
Limb girdle muscular dystrophies (LGMDs) are a group of rare genetic disorders characterized by a progressive dystrophic phenotype, mainly affecting the muscles of the shoulder and pelvic areas. Onset and severity of the symptoms are variable. Typical LGMD signs are difficulty in movements, wobbling gait and specific distribution of muscle atrophy.Read more
The management team of Atamyo is seasoned team of professionals with extensive experience in biotech and gene therapy.Read more
Atamyo Therapeutics announces Significant Milestones for ATA-100 and ATA-200, its Gene Therapy programs to Treat Limb-Girdle Muscular Dystrophy 2I/R9 and 2C/R5
Additional approval of Clinical Trial Application for ATA-100 received from French National Medicines Health Agency (ANSM) Orphan Drug Designation awarded from European EMA for ATA-200 Forthcoming presentation on ATA-200 at ASGCT annual meeting Appointment of […]